2021;44(Supplement_1):S11124
Key results at 80 weeks: Participants on the 4 mg dose lost an average of 47.2 lbs (19.0%) Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) 45.3% of participants on the 12 mg dose achieved at least 30% weight loss a level historically associated with bariatric surgery outcomes The 4 mg dose showed a lower rate of discontinuation due to adverse events than even placebo In a study extension to 104 weeks, participants with a starting BMI of 35 or higher who received 12 mg lost up to an average of 85.0 lbs (30.3%)
All of these things combined may help you feel more satisfied after eating, allowing you to limit your snacking throughout the day and consume fewer calories
Other promising drugs to reduce appetite and increase energy expenditure in patients with PWS were Sibutramine, an unspecific inhibitor of serotonin and norepinephrine reuptake, and Rimonabant, an endocannabinoid CB1 receptor antagonist
Pros: Long track record of safety
Location: Philadelphia, PA Amanda Marie Hitz One-trial nongustatory conditioned-sickness learning in day-old chicks
